Turning Point Therapeutics's ROA from the second quarter of 2022 to the second quarter of 2021 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics

What is Turning Point Therapeutics's ROA in the second quarter of 2022?
Turning Point Therapeutics Inc. recorded a cumulative net loss of $-342 million during 12 months ending in the second quarter of 2022, resulting in a negative return on assets (ROA) of -35.61%.

However, within the Healthcare sector 653 other companies had a higher return on assets. While return on assets, the total ranking has deteriorated compared to the first quarter of 2022 from 4521 to 4784.

What is ROA?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Assets ROA▼

None ▼

Return on Assets ROA▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Assets	(Jun 30 2022) II. Quarter	(Mar 31 2022) I. Quarter	(Dec 31 2021) IV. Quarter	(Sep 30 2021) III. Quarter	(Jun 30 2021) II. Quarter
Y / Y Total Assets Change	-23.52 %	-16.74 %	-45.94 %	46.14 %	52.83 %
Y / Y Net Income Change	-	-	-	-	-
Net Income (TTM) in million	-342	-275	-237	-205	-157
Return On Assets (TTM)	-35.61 %	-26.85 %	-22.04 %	-15.97 %	-13.04 %
TPTX's Total Ranking	# 4784	# 4521	# 4694	# 3811	# 3753
Total Assets (TTM) in million	843	939	1,003	1,059	1,103
Seq. Total Assets Change	-10.17 %	-6.45 %	-5.24 %	-3.96 %	-2.21 %
Seq. Net Income Change	-	-	-	-	-

TPTX's 5 Years Annual ROA >> Back to TPTX Management Effectiveness >> Compare TPTX ROA to its Competitors

Return On Assets Company Ranking
Within:	No.
Industry	# 272
Sector	# 654
Overall	# 4670

Return On Assets Statistics
High	Average	Low
-14.22 %	-24.41 %	-35.61 %
(Mar 31 2021)		(Jun 30 2022)

Financial Statements
Turning Point Therapeutics's Assets	$ 843 million	TPTX's Balance sheet
Turning Point Therapeutics's Income	$ -123 million	Quarterly TPTX's Income Statement
TPTX's Income by Division		See TPTX's Income by Division

Annual Return On Assets	(Dec 31 2021) FY 2021	(Dec 31 2020) FY 2020	(Dec 31 2019) FY 2019	FY	FY
Y / Y Total Assets Change	-45.94 %	339.61 %	-	-	-
Total Assets in million	1,003	1,856	422	0	0
Y / Y Net Income Change	-	-	-	-	-
Net Income in million	-237	-157	-72	0	0
Annual Return On Assets	-23.57 %	-8.47 %	-17.08 %	-	-

TPTX's 5 Years Annual ROA >> Back to TPTX Management Effectiveness >> Compare TPTX ROA to its Competitors

More Return On Assets Ratios
TPTX's' Return on Assets at Yahoo Finance
Major Pharmaceutical Preparations Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
TPTX's Roa Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for TPTX's Competitors
Subscribers only: Roa for Turning Point Therapeutics's Suppliers
Subscribers only: Return On Assets for TPTX's Customers

You may also want to know
TPTX's Roi	TPTX's Inventory Turnover Ratio	TPTX's Growth Rates	TPTX's Dividend Comparisons
	TPTX's Profitability Ratios	TPTX's Asset Turnover Ratio	TPTX's Dividend Growth
TPTX's Roe	TPTX's Valuation Ratios	TPTX's Financial Strength Ratios	TPTX's Dividend Payout Ratio

Companies with similar Return On Assets at Jun 30 2022, within Healthcare Sector

ROA

Date modified: 2026-09-18T13:11:05+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.